The core objectives of a drug delivery system are to achieve precise targeting, controlled release, and the reduction of toxic side effects. The performance of the carrier material directly determines the efficiency of the entire system. Nano magnesium oxide (nano-MgO), with its unique physicochemical properties, offers irreplaceable advantages in drug delivery. Its roles span across multiple dimensions, including carrier loading, targeted delivery, controlled release, and the enhancement of biocompatibility, providing critical support for the development of novel pharmaceutical formulations.
1. High-Efficiency Drug Loading Capacity
As a drug carrier, nano-MgO possesses exceptional loading capabilities. It features an ultra-high specific surface area (reaching 150-300 m²/g) and abundant surface hydroxyl groups. These allow it to bind with drug molecules through various mechanisms, such as electrostatic interaction, hydrogen bonding, and physical adsorption. Its loading capacity is 3 to 5 times higher than that of traditional micron-sized carriers. For anti-tumor drugs with poor water solubility (such as Docetaxel and Paclitaxel), the porous structure of nano-MgO can form a “drug reservoir,” significantly improving drug solubility and bioavailability.
Experimental data shows that nano-MgO with a particle size of 50 nm can achieve a loading capacity of 280 mg/g for Paclitaxel—far exceeding the 80 mg/g capacity of traditional Poly(lactic-co-glycolic acid) (PLGA) carriers. This high-loading characteristic reduces the amount of carrier required, lowers the side effects of the formulation, and enhances the therapeutic efficacy per unit dose. Furthermore, the surface charge of nano-MgO can be adjusted via pH levels, making it easier to optimize loading conditions for different drug molecules.
2. Precision Targeted Delivery
Targeted delivery is one of the core values of nano-MgO in drug delivery systems. Through surface modification technologies, targeting ligands (such as folic acid, transferrin, or monoclonal antibodies) can be attached to the surface of nano-MgO. This allows the drug to concentrate precisely at the lesion site, minimizing damage to healthy tissues.
In cancer treatment, for example, folic acid-modified nano-MgO can recognize folic acid receptors that are overexpressed on the surface of tumor cells. Through receptor-mediated endocytosis, the particles enter the cells to achieve targeted drug release. This mechanism can increase the drug concentration at the tumor site by 10 to 20 times compared to traditional formulations. For inflammatory diseases, nano-MgO can be modified with integrin receptor antagonists to target inflamed tissues specifically, reducing the systemic side effects associated with general medication.
3. pH-Responsive Intelligent Controlled Release
Nano-MgO exhibits pH-responsive release characteristics, enabling “smart” drug delivery. Its solubility varies significantly across different pH environments:
- In Acidic Environments: Such as the tumor microenvironment (pH 6.0–6.5) or intracellular lysosomes (pH 4.5–5.5), nano-MgO gradually dissolves and releases the drug.
- In Neutral Physiological Environments: At pH 7.4, it remains stable, with a drug leakage rate of less than 5%.
This pH-responsive property ensures “on-demand release” at the site of the disease, preventing premature leakage during transport and improving drug utilization. For instance, in oral enteric-coated formulations, nano-MgO-loaded drugs can pass safely through the stomach’s acidic environment (pH 1.2–3.0) and release slowly upon reaching the intestines (pH 7.0–8.0). This protects the drug from gastric acid while reducing irritation to the gastric mucosa. In tumor therapy, once nano-MgO enters the cell, it dissolves rapidly in the acidic lysosome, releasing the drug to induce apoptosis while the resulting magnesium ions help regulate the intracellular environment to enhance the killing effect.
4. Enhancement of Biocompatibility and Safety
Nano-MgO improves the biocompatibility and safety of delivery systems. Magnesium is an essential trace element for the human body, participating in numerous physiological metabolic processes. Nano-MgO can be slowly degraded into magnesium ions (Mg²⁺) in the body and excreted normally through the kidneys, showing no significant cumulative toxicity. Cellular experiments indicate that at concentrations below 200 μg/mL, nano-MgO exhibits extremely low toxicity to liver cells and red blood cells, with a hemolysis rate of less than 1%, meeting safety standards for biomedical materials.
Additionally, the inherent anti-inflammatory and antibacterial properties of nano-MgO can assist in treating infectious or inflammation-related diseases. In antibiotic delivery systems, the antibacterial activity of nano-MgO can work synergistically with antibiotics, reducing the risk of bacterial resistance and improving treatment outcomes.
Clinical Progress and Future Outlook
Currently, nano-MgO drug delivery systems are undergoing clinical trials in several fields:
- Lung Cancer: Folate-modified nano-MgO-Paclitaxel formulations have increased tumor volume shrinkage rates by 40% while reducing the incidence of side effects like nausea and hair loss by 60%.
- Ulcerative Colitis: Oral pH-responsive nano-MgO-Sulfasalazine formulations have improved intestinal inflammation remission rates by 35%.
Despite its massive potential, challenges remain, such as achieving uniformity in surface modification and optimizing large-scale manufacturing processes. In the future, by integrating with technologies like gene delivery and photothermal therapy, nano-MgO is expected to achieve even broader applications in the field of precision medicine.